Effects of As2O3 and Resveratrol on the Proliferation and Apoptosis of Colon Cancer Cells and the hERG-mediated Potential Mechanisms

Author(s): Caichuan Yan*, Fengmei Li*, Yuhao Zhang, Yang Li, Mingzhu Li, Fang Wang, Guocui Zhang, Yuexin Li, Baoxin Li, Xin Zhao

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 12 , 2019

Become EABM
Become Reviewer
Call for Editor


Background: As2O3 and resveratrol have been widely considered to be effective in anti-cancer therapies and the underlying mechanisms have been reported extensively. However, the combined treatment effect and potential target of As2O3 and resveratrol in the treatment of tumors remains elusive. The purpose of this study was to investigate the benefits and efficacy of As2O3 in combination with resveratrol in the treatment of colon cancer, as well as looking for new targets that could provide alternative explanation of the efficacy of drugs.

Methods: The proliferation of cancer cells was measured by the MTT and EdU staining assay, while the apoptosis of cancer cells was determined by the flow cytometry. Western blot and immunoprecipitation were performed to measure the expression levels of proteins and the interaction between hERG and integrin β1, respectively.

Results: In this study, we found that both As2O3 and resveratrol can effectively inhibit cell proliferation and promote cell apoptosis in colon cancer, and the combined effect of the two drugs on colon cancer cells is more preeminent. The combination of As2O3 with resveratrol, on the one hand reduced the expression of hERG channels on the membrane, and on the other hand weaken the binding between hERG and integrin β 1, which may be the main cause of downstream signaling pathways alterations, including the activation of the apoptotic pathway.

Conclusion: Taken together, hERG, as a subunit of potassium ion channel on the cell membrane, is highly likely to be involved in the As2O3 and resveratrol induced intracellular signaling cascade disorder, and this novel signaling pathway that sustains the progression of colon cancer may be a promising therapeutic target for human colon cancer treatment in the future.

Keywords: hERG, β1 integrin, proliferation, apoptosis, colon cancer, resveratrol.

Eguether T, Hahne M. Mixed signals from the cell’s antennae: primary cilia in cancer. EMBO Rep 2018; 19(11): e46589. [http://dx.doi.org/10.15252/embr.201846589]. [PMID: 30348893].
Babiker HM, McBride A, Newton M, et al. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol 2018; 126: 186-200. [http://dx.doi.org/10.1016/j.critrevonc.2018.03.014]. [PMID: 29759560].
Xia J, Wang H, Li S, et al. Ion channels or aquaporins as novel molecular targets in gastric cancer. Mol Cancer 2017; 16(1): 54. [http://dx.doi.org/10.1186/s12943-017-0622-y]. [PMID: 28264681].
Pardo LA, Stühmer W. The roles of K(+) channels in cancer. Nat Rev Cancer 2014; 14(1): 39-48. [http://dx.doi.org/10.1038/nrc3635]. [PMID: 24336491].
D’Amico M, Gasparoli L, Arcangeli A. Potassium channels: novel emerging biomarkers and targets for therapy in cancer. Recent Patents Anticancer Drug Discov 2013; 8(1): 53-65. [http://dx.doi.org/10.2174/1574892811308010053]. [PMID: 22574647].
Arcangeli A, Becchetti A. hERG Channels: From antitargets to novel targets for cancer therapy. Clin Cancer Res 2017; 23(1): 3-5. [http://dx.doi.org/10.1158/1078-0432.CCR-16-2322]. [PMID: 27903676].
Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis 2011; 2e193. [http://dx.doi.org/10.1038/cddis.2011.77] [PMID: 21850047]
Pillozzi S, D’Amico M, Bartoli G, et al. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. Br J Cancer 2018; 118(2): 200-12. [http://dx.doi.org/10.1038/bjc.2017.392]. [PMID: 29161243].
Fortunato A. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells. Cell Oncol (Dordr) 2017; 40(4): 367-78. [http://dx.doi.org/10.1007/s13402-017-0328-6]. [PMID: 28593575].
Lastraioli E, Lottini T, Bencini L, Bernini M, Arcangeli A. hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers. BioMed Res Int 2015; 2015: 896432. [http://dx.doi.org/10.1155/2015/896432]. [PMID: 26339650].
Patanè S. HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014; 176(3): 1082-5. [http://dx.doi.org/10.1016/j.ijcard.2014.07.129]. [PMID: 25218820].
Babcock JJ, Li M. hERG channel function: beyond long QT. Acta Pharmacol Sin 2013; 34(3): 329-35. [http://dx.doi.org/10.1038/aps.2013.6]. [PMID: 23459091].
Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol Rep 2010; 23(6): 1747-56. [PMID: 20428834].
Liao YH, Li CI, Lin CC, Lin JG, Chiang JH, Li TC. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017; 143(12): 2425-35. [http://dx.doi.org/10.1007/s00432-017-2491-6]. [PMID: 28803328].
Wong R, Sagar CM, Sagar SM. Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001; 27(4): 235-46. [http://dx.doi.org/10.1053/ctrv.2001.0227]. [PMID: 11545543].
Chu W, Li C, Qu X, et al. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome. Cardiovasc Res 2012; 96(1): 90-8. [http://dx.doi.org/10.1093/cvr/cvs230]. [PMID: 22853924].
Yan M, Feng L, Shi Y, et al. Mechanism of As2O3-induced action potential prolongation and using hiPS-CMs to evaluate the rescue efficacy of drugs with different rescue mechanism. Toxicol Sci 2017; 158(2): 379-90. [http://dx.doi.org/10.1093/toxsci/kfx098]. [PMID: 28521025].
Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia 2018; 32(6): 1277-94. [http://dx.doi.org/10.1038/s41375-018-0139-4]. [PMID: 29743722].
Huminiecki L, Horbańczuk J. The functional genomic studies of resveratrol in respect to its anti-cancer effects. Biotechnol Adv 2018; 36(6): 1699-708. [http://dx.doi.org/10.1016/j.biotechadv.2018.02.011]. [PMID: 29476886].
Lastraioli E, Guasti L, Crociani O, et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004; 64(2): 606-11. [http://dx.doi.org/10.1158/0008-5472.CAN-03-2360]. [PMID: 14744775].
Cherubini A, Hofmann G, Pillozzi S, et al. Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling. Mol Biol Cell 2005; 16(6): 2972-83. [http://dx.doi.org/10.1091/mbc.e04-10-0940]. [PMID: 15800067].

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 08 August, 2019
Page: [1385 - 1391]
Pages: 7
DOI: 10.2174/1381612817666190619123610

Article Metrics

PDF: 43